was read the article
array:21 [ "pii" => "X0873215915188377" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2015.04.002" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:111-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3995 "formatos" => array:3 [ "EPUB" => 236 "HTML" => 2654 "PDF" => 1105 ] ] "itemSiguiente" => array:16 [ "pii" => "X0873215915188385" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2014.09.009" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:113-25" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5455 "formatos" => array:3 [ "EPUB" => 224 "HTML" => 4239 "PDF" => 992 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "113" "paginaFinal" => "125" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "Case 21: 2+ CK20 expression; acinar pattern. 200×." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Vitor Sousa, Carolina Rodrigues, Maria Silva, Ana Maria Alarcão, Lina Carvalho" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Vitor" "apellidos" => "Sousa" ] 1 => array:2 [ "nombre" => "Carolina" "apellidos" => "Rodrigues" ] 2 => array:2 [ "nombre" => "Maria" "apellidos" => "Silva" ] 3 => array:2 [ "nombre" => "Ana Maria" "apellidos" => "Alarcão" ] 4 => array:2 [ "nombre" => "Lina" "apellidos" => "Carvalho" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188385?idApp=UINPBA00004E" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188385/v0_201604141146/en/main.assets" ] "itemAnterior" => array:16 [ "pii" => "X0873215915188369" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2015.04.001" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:109-10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3162 "formatos" => array:3 [ "EPUB" => 238 "HTML" => 1987 "PDF" => 937 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Routine characterization of biomarkers in non-small cell lung carcinoma: how much is enough?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "109" "paginaFinal" => "110" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José Carlos Machado" "autores" => array:1 [ 0 => array:2 [ "nombre" => "José Carlos" "apellidos" => "Machado" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188369?idApp=UINPBA00004E" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188369/v0_201604141146/en/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S2173511515000226" "issn" => "21735115" "doi" => "10.1016/j.rppnen.2014.07.004" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "1026" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "sco" "cita" => "Rev Port Pneumol. 2015;21:151-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1935 "formatos" => array:3 [ "EPUB" => 253 "HTML" => 1166 "PDF" => 516 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief Communication</span>" "titulo" => "Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "151" "paginaFinal" => "156" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1765 "Ancho" => 1667 "Tamanyo" => 166595 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Analysis over the 24 months of treatment period. (a) Effect on asthma control as measured by investigator assessment; (b) effect on reduction in corticosteroid requirement. Values are for the week before specified time points.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Pereira Barbosa, A. Bugalho de Almeida, C. Pereira, C.-W. Chen, P. Georgiou, G. Peachey" "autores" => array:7 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Pereira Barbosa" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Bugalho de Almeida" ] 2 => array:2 [ "nombre" => "C." "apellidos" => "Pereira" ] 3 => array:2 [ "nombre" => "C.-W." "apellidos" => "Chen" ] 4 => array:2 [ "nombre" => "P." "apellidos" => "Georgiou" ] 5 => array:2 [ "nombre" => "G." "apellidos" => "Peachey" ] 6 => array:1 [ "colaborador" => "on behalf of eXpeRience study group" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511515000226?idApp=UINPBA00004E" "url" => "/21735115/0000002100000003/v2_201505070217/S2173511515000226/v2_201505070217/en/main.assets" ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Omalizumab: a treatment for severe asthma in real life?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "111" "paginaFinal" => "112" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Anaïs Briquet, Pascal Chanez" "autores" => array:2 [ 0 => array:3 [ "nombre" => "Anaïs" "apellidos" => "Briquet" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:4 [ "nombre" => "Pascal" "apellidos" => "Chanez" "email" => array:1 [ 0 => "pascal.chanez@univ-amu.fr" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Département des Maladies Respiratoires, AP-HM, INSERM CNRS U 1067, UMR7733, Aix Marseille Université, Marseille, France" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "<span class="elsevierStyleSup">*</span>" "correspondencia" => "Corresponding author. pascal.chanez@univ-amu.fr" ] ] ] ] "textoCompleto" => "<p class="elsevierStylePara">In 2015, asthma remains an important health problem. It is costly: first as a chronic disorder it represents a significant burden for the patients and their relatives; secondly due to management of disease including controller medications and what is required for acute exacerbations i.e.: hospitalizations and days off work Overall, while mortality has certainly decreased, most of our current treatments are still primarily symptom based and do not alter with the natural history of the disease. Meanwhile, severe asthma remains a challenge, as most patients with this type of asthma remain uncontrolled despite a real diagnosis, a fair compliance and an important need of existing therapies with known side effects.</p><p class="elsevierStylePara">Total IgE has been linked to asthma in epidemiological studies and was considered to be associated with an allergic phenotype of the disease. More recently, it has been shown to be a part of the high TH2 group of potential biomarkers, such as eNO and blood eosinophils, in predecting future risk including recurrent exacerbations. IgE and IgE receptors play a part in the pathophysiology of asthma by activating various effector cells even in non- allergic situations. Very recently an epigenome association with total IgE was reported, and methylated genes encoding for eosinophil products were connected in a reproducible way. The results were confirmed by isolated eosinophils from patients with high eosinophilia and asthma. This type of study will certainly point towards new types of mechanisms, which will allow a more personalized way to treat asthma.<a href="#bib1" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a></p><p class="elsevierStylePara">Omalizumab has been shown in several well-performed studies to decrease the exacerbation rate in severe uncontrolled allergic asthma.<a href="#bib2" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">2</span></a> It has been used with success to treat mild asthma and allergic rhinitis and to prevent seasonal exacerbations in patients with a broad range of severity.<a href="#bib3" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a> Randomized control studies are helpful to demonstrate the efficacy and safety of new drugs. They are the bottom line of marketing in westernized countries. They sustain the different guidelines, but even though most of the recommendations are based on randomized control studies, most of the patients with severe asthma are not qualified to enter RCP studies.<a href="#bib4" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">4</span></a> Therefore large pragmatic trials with real life conditions are currently more popular. These trials will try to demonstrate efficiency and include a large numbers of patients. They will enroll patients with less strict criteria, closer a real clinical situation and allow a longitudinal follow-up with pertinent outcomes.<a href="#bib5" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">5</span></a><span class="elsevierStyleSup">, </span><a href="#bib6" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">6</span></a></p><p class="elsevierStylePara">In this issue of the journal, taking advantage of the EXperience study,<a href="#bib7" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">7</span></a> our Portuguese colleagues have considered 62 patients from their own country to demonstrate an overall 60% satisfaction with the treatment, with a fair control of asthma including daily symptoms and exacerbations. The treatment improves health related quality of life but has little impact on lung function. This study describes an interesting observation and confirms the larger study from Grimaldi Bensoussa et al, reporting the real improvement seen in the initial Innovate study.<a href="#bib8" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">8</span></a> The number of severe exacerbations and the need for oral corticosteroid upsurges were significantly decreased in this real life study of omalizumab treated patients as compared to the reference arm. We can postulate that omalizumab is a well-established treatment in Europe for severe asthma. It is advocated by the GINA guidelines and the ATS/ERS task force on severe asthma, however as a specific biotherapy it requires more investigation.<a href="#bib9" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">9</span></a> It would be worth knowing if we can confirm its efficacy in non-allergic severe asthma.<a href="#bib10" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">10</span></a> We are all fighting to improve antecipation of the response to the intervention. At present, we need specific biomarkers with an impact on future risk. Last of all, it is important to assess the potential for these interventions to go along with asthma remission, but recent studies are not very encouraging. Omalizumab is the first efficient and safe biotherapy for severe asthma with the potential to be used in this disease. We should continue to question how it works and to report efficiency data from large real life cohort studies.</p><p class="elsevierStylePara">Corresponding author. pascal.chanez@univ-amu.fr</p>" "pdfFichero" => "320v21n03a90418837pdf001.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "An epigenome-wide association study of total serum immunoglobulin E concentration. Nature. 2015. Feb 18. doi: 10.1038/nature14125. [Epub ahead of print]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "An epigenome-wide association study of total serum immunoglobulin E concentration." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Liang L" 1 => "Willis-Owen SAG" 2 => "Laprise C" 3 => "Wong KCC" 4 => "Davies GA" 5 => "Hudson TJ" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Nature. " "fecha" => "2015" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014; 2:525-36. e1" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Omalizumab in asthma: an update on recent developments." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Humbert M" 1 => "Busse W" 2 => "Hanania NA" 3 => "Lowe PJ" 4 => "Canvin J" 5 => "Erpenbeck VJ" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaip.2014.03.010" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol Pract. " "fecha" => "2014" "volumen" => "2" "paginaInicial" => "525" "paginaFinal" => "536" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25213045" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. N Engl J Med. 2011; 364:1005-15." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Busse WW" 1 => "Morgan WJ" 2 => "Gergen PJ" 3 => "Mitchell HE" 4 => "Gern JE" 5 => "Liu AH" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1009705" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2011" "volumen" => "364" "paginaInicial" => "1005" "paginaFinal" => "1015" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21410369" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "External Validity of Randomized Controlled Trials in Severe Asthma. AJRCCM. 2015. in press." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "External Validity of Randomized Controlled Trials in Severe Asthma." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Pahus L" 1 => "Alagha K" 2 => "Sofalvi T" 3 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "AJRCCM. " "fecha" => "2015" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Can randomised trials inform clinical decisions about individual patients?. Lancet. 1999; 353:743-6." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Can randomised trials inform clinical decisions about individual patients?." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Mant D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(98)09102-8" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "1999" "volumen" => "353" "paginaInicial" => "743" "paginaFinal" => "746" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10073531" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Asthma treatment guidelines meet the real world. N Engl J Med. 2011; 364:1769-70." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Asthma treatment guidelines meet the real world." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Dahlén S-E" 1 => "Dahlén B" 2 => "Drazen JM." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMe1100937" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2011" "volumen" => "364" "paginaInicial" => "1769" "paginaFinal" => "1770" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21542748" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The eXpeRience registry: the “real-world” effectiveness of omalizumab in allergic asthma. Respir Med. 2013; 107:1141-51." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The eXpeRience registry: the “real-world” effectiveness of omalizumab in allergic asthma." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Braunstahl G-J" 1 => "Chen C-W" 2 => "Maykut R" 3 => "Georgiou P" 4 => "Peachey G" 5 => "Bruce J." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rmed.2013.04.017" "Revista" => array:6 [ "tituloSerie" => "Respir Med. " "fecha" => "2013" "volumen" => "107" "paginaInicial" => "1141" "paginaFinal" => "1151" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23721684" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Does omalizumab make a difference to the real-life treatment of asthma exacerbations?.: Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013; 143:398-405." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Does omalizumab make a difference to the real-life treatment of asthma exacerbations?.: Results from a large cohort of patients with severe uncontrolled asthma." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Grimaldi-Bensouda L" 1 => "Zureik M" 2 => "Aubier M" 3 => "Humbert M" 4 => "Levy J" 5 => "Benichou J" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest. " "fecha" => "2013" "volumen" => "143" "paginaInicial" => "398" "paginaFinal" => "405" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23505637" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "European Respiratory Society/American Thoracic Society Severe Asthma International Guidelines Task Force. From the authors: International European Respiratory Society/American Thoracic Society guidelines on severe asthma. Eur Respir J. 2014; 44:1378-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "European Respiratory Society/American Thoracic Society Severe Asthma International Guidelines Task Force. From the authors: International European Respiratory Society/American Thoracic Society guidelines on severe asthma." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Chung KF" 1 => "Wenzel S." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00120714" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J. " "fecha" => "2014" "volumen" => "44" "paginaInicial" => "1378" "paginaFinal" => "1379" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25362128" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013; 144:411-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Garcia G" 1 => "Magnan A" 2 => "Chiron R" 3 => "Contin-Bordes C" 4 => "Berger P" 5 => "Taillé C" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.12-1961" "Revista" => array:6 [ "tituloSerie" => "Chest. " "fecha" => "2013" "volumen" => "144" "paginaInicial" => "411" "paginaFinal" => "419" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23579324" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188377/v0_201604141146/en/main.assets" "Apartado" => array:4 [ "identificador" => "18132" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editoriais" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/08732159/0000002100000003/v0_201604141146/X0873215915188377/v0_201604141146/en/320v21n03a90418837pdf001.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188377?idApp=UINPBA00004E" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 9 | 9 | 18 |
2024 October | 37 | 32 | 69 |
2024 September | 27 | 21 | 48 |
2024 August | 47 | 36 | 83 |
2024 July | 42 | 33 | 75 |
2024 June | 52 | 18 | 70 |
2024 May | 46 | 37 | 83 |
2024 April | 41 | 36 | 77 |
2024 March | 30 | 24 | 54 |
2024 February | 35 | 25 | 60 |
2024 January | 22 | 24 | 46 |
2023 December | 25 | 23 | 48 |
2023 November | 27 | 32 | 59 |
2023 October | 25 | 39 | 64 |
2023 September | 25 | 28 | 53 |
2023 August | 20 | 17 | 37 |
2023 July | 28 | 24 | 52 |
2023 June | 16 | 18 | 34 |
2023 May | 44 | 28 | 72 |
2023 April | 29 | 22 | 51 |
2023 March | 66 | 19 | 85 |
2023 February | 46 | 27 | 73 |
2023 January | 19 | 18 | 37 |
2022 December | 37 | 17 | 54 |
2022 November | 49 | 38 | 87 |
2022 October | 47 | 31 | 78 |
2022 September | 21 | 29 | 50 |
2022 August | 33 | 38 | 71 |
2022 July | 28 | 46 | 74 |
2022 June | 18 | 33 | 51 |
2022 May | 28 | 38 | 66 |
2022 April | 19 | 30 | 49 |
2022 March | 28 | 46 | 74 |
2022 February | 25 | 41 | 66 |
2022 January | 26 | 33 | 59 |
2021 December | 22 | 36 | 58 |
2021 November | 26 | 31 | 57 |
2021 October | 36 | 47 | 83 |
2021 September | 23 | 28 | 51 |
2021 August | 22 | 20 | 42 |
2021 July | 25 | 20 | 45 |
2021 June | 14 | 24 | 38 |
2021 May | 26 | 29 | 55 |
2021 April | 63 | 58 | 121 |
2021 March | 49 | 20 | 69 |
2021 February | 50 | 13 | 63 |
2021 January | 24 | 11 | 35 |
2020 December | 16 | 6 | 22 |
2020 November | 35 | 17 | 52 |
2020 October | 30 | 12 | 42 |
2020 September | 46 | 22 | 68 |
2020 August | 57 | 24 | 81 |
2020 July | 80 | 21 | 101 |
2020 June | 63 | 15 | 78 |
2020 May | 68 | 16 | 84 |
2020 April | 52 | 10 | 62 |
2020 March | 50 | 14 | 64 |
2020 February | 52 | 23 | 75 |
2020 January | 69 | 21 | 90 |
2019 December | 60 | 24 | 84 |
2019 November | 62 | 21 | 83 |
2019 October | 73 | 24 | 97 |
2019 September | 54 | 14 | 68 |
2019 August | 109 | 19 | 128 |
2019 July | 97 | 13 | 110 |
2019 June | 110 | 19 | 129 |
2019 May | 107 | 16 | 123 |
2019 April | 106 | 22 | 128 |
2019 March | 93 | 10 | 103 |
2019 February | 108 | 11 | 119 |
2019 January | 108 | 24 | 132 |
2018 December | 50 | 7 | 57 |
2018 November | 13 | 0 | 13 |
2018 October | 22 | 10 | 32 |
2018 September | 18 | 9 | 27 |
2018 August | 31 | 25 | 56 |
2018 July | 33 | 24 | 57 |
2018 June | 38 | 22 | 60 |
2018 May | 54 | 20 | 74 |
2018 April | 68 | 20 | 88 |
2018 March | 57 | 16 | 73 |
2018 February | 26 | 11 | 37 |
2018 January | 12 | 13 | 25 |
2017 December | 48 | 18 | 66 |
2017 November | 18 | 24 | 42 |
2017 October | 22 | 13 | 35 |
2017 September | 18 | 19 | 37 |
2017 August | 22 | 15 | 37 |
2017 July | 16 | 11 | 27 |
2017 June | 30 | 20 | 50 |
2017 May | 27 | 17 | 44 |
2017 April | 13 | 8 | 21 |
2017 March | 12 | 8 | 20 |
2017 February | 9 | 4 | 13 |
2017 January | 14 | 9 | 23 |
2016 December | 15 | 10 | 25 |
2016 November | 6 | 5 | 11 |
2016 October | 8 | 6 | 14 |
2016 September | 2 | 0 | 2 |
2016 August | 2 | 3 | 5 |
2016 July | 3 | 8 | 11 |
2016 June | 0 | 5 | 5 |
2016 May | 0 | 4 | 4 |
2016 April | 29 | 2 | 31 |
2016 March | 46 | 31 | 77 |
2016 February | 51 | 31 | 82 |
2016 January | 39 | 28 | 67 |
2015 December | 49 | 26 | 75 |
2015 November | 32 | 21 | 53 |
2015 October | 44 | 36 | 80 |
2015 September | 47 | 43 | 90 |
2015 August | 59 | 42 | 101 |
2015 July | 65 | 33 | 98 |
2015 June | 86 | 46 | 132 |
2015 May | 215 | 125 | 340 |